GE HealthCare Technologies (NASDAQ:GEHC) Price Target Raised to $79.00

GE HealthCare Technologies (NASDAQ:GEHC) had its price objective upped by BTIG Research from $75.00 to $79.00 in a research note issued to investors on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

GEHC has been the subject of several other research reports. Royal Bank Of Canada assumed coverage on shares of GE HealthCare Technologies in a research note on Tuesday, June 23rd. They set an “outperform” rating and a $80.00 price target for the company. Hovde Group initiated coverage on GE HealthCare Technologies in a research note on Friday, July 17th. They issued a “market perform” rating and a $14.00 price objective on the stock. Stifel Nicolaus set a $80.00 target price on GE HealthCare Technologies in a report on Wednesday, April 29th. Zacks Research downgraded GE HealthCare Technologies from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Finally, Mizuho decreased their price target on GE HealthCare Technologies from $90.00 to $80.00 in a research note on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $77.73.

GE HealthCare Technologies Price Performance

GEHC stock opened at $68.02 on Wednesday. GE HealthCare Technologies has a one year low of $58.75 and a one year high of $89.77. The firm has a 50-day moving average of $64.02 and a two-hundred day moving average of $70.55. The firm has a market capitalization of $30.94 billion, a PE ratio of 15.60, a P/E/G ratio of 1.90 and a beta of 0.72. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 0.92.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its earnings results on Wednesday, July 29th. The company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a return on equity of 20.12% and a net margin of 9.33%.The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.26 billion. During the same period in the prior year, the firm posted $1.06 EPS. The business’s revenue was up 5.8% compared to the same quarter last year. On average, analysts forecast that GE HealthCare Technologies will post 4.89 earnings per share for the current year.

GE HealthCare Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Friday, July 24th will be issued a $0.035 dividend. This represents a $0.14 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, July 24th. GE HealthCare Technologies’s dividend payout ratio is presently 3.21%.

Insider Transactions at GE HealthCare Technologies

In other news, Director Rodney F. Hochman bought 1,618 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were bought at an average price of $62.03 per share, with a total value of $100,364.54. Following the completion of the transaction, the director owned 1,618 shares of the company’s stock, valued at $100,364.54. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kevin Lobo bought 10,000 shares of the stock in a transaction dated Friday, May 22nd. The shares were acquired at an average cost of $64.18 per share, for a total transaction of $641,800.00. Following the completion of the acquisition, the director directly owned 14,363 shares of the company’s stock, valued at approximately $921,817.34. This trade represents a 229.20% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 12,618 shares of company stock worth $805,175. 0.36% of the stock is owned by company insiders.

Institutional Investors Weigh In On GE HealthCare Technologies

Large investors have recently added to or reduced their stakes in the business. Western Wealth Management LLC lifted its stake in GE HealthCare Technologies by 2.4% in the fourth quarter. Western Wealth Management LLC now owns 5,240 shares of the company’s stock valued at $430,000 after purchasing an additional 125 shares during the last quarter. United Community Bank raised its stake in shares of GE HealthCare Technologies by 10.2% in the fourth quarter. United Community Bank now owns 1,410 shares of the company’s stock valued at $116,000 after buying an additional 130 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of GE HealthCare Technologies by 3.9% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,567 shares of the company’s stock valued at $293,000 after buying an additional 134 shares during the period. Quadrant Capital Group LLC lifted its position in shares of GE HealthCare Technologies by 1.1% during the 4th quarter. Quadrant Capital Group LLC now owns 12,557 shares of the company’s stock valued at $1,030,000 after buying an additional 140 shares during the last quarter. Finally, Mount Vernon Associates Inc. MD lifted its position in shares of GE HealthCare Technologies by 0.8% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 18,165 shares of the company’s stock valued at $1,293,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies News Summary

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Better-than-expected earnings and raised guidance: GE HealthCare reported adjusted earnings of $1.13 per share, exceeding the $1.04 consensus estimate, while revenue of $5.30 billion also topped expectations. Revenue increased 5.8% year over year, and management raised its full-year EPS outlook. GE HealthCare Q2 2026 Earnings Call Summary
• Positive Sentiment: Record backlog and solid demand: Strong orders growth and a record backlog support expectations for future revenue growth and helped reinforce the bullish case for GEHC. Analysts highlighted the backlog as evidence of durable demand for the company’s medical technology and imaging products. GE HealthCare Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support increased: Wells Fargo raised its price target from $75 to $85 and maintained an “overweight” rating. BTIG Research also forecast substantial appreciation, providing additional support for the shares. Wells Fargo Raises GE HealthCare Price Target
• Neutral Sentiment: Execution remains a key issue: Some analysis described demand as strong but execution as weaker, suggesting investors will watch margins, delivery performance and the company’s ability to convert its backlog into sustained earnings growth. GE HealthCare Strong Demand, Weak Execution
• Negative Sentiment: Shareholder investigations create legal uncertainty: Multiple law firms announced or continued investigations into possible securities-law violations and solicited investors who lost money. These announcements do not establish wrongdoing, but they may weigh on sentiment and raise potential litigation concerns. GEHC Securities Fraud Investigation

About GE HealthCare Technologies

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.